Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Regulated information – inside informationNazareth...
Disclosure of notification received from FMR LLC Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM...
Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook Regulated information - inside...
Disclosure of notification received from AOC Pharma S.à r.l. Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 October 2024...
Fagron completes share buy-back program Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 September 2024 – 6PM CET Fagron...
Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 September 2024 – 6PM CET...
Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 30 August 2024 – 6PM CET...
Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 August 2024 – 6PM CET...
Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024 Regulated information - inside...
Fagron shareholders approve all voting items at AGM and EGM Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 May 2024...
Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting Regulated information Nazareth...
Record revenue of €209 million in first quarter reflecting 15% topline growth Regulated information - inside informationNazareth...
Disclosure notification from Mawer Investment Management Ltd. Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 March...
Fagron publishes annual report 2023 Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 March 2024 – 6:30 PM CET Fagron...
Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023 Regulated information – inside...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads